CN1089232C - 将微水溶性药物转化为非晶态的方法 - Google Patents

将微水溶性药物转化为非晶态的方法 Download PDF

Info

Publication number
CN1089232C
CN1089232C CN96196203A CN96196203A CN1089232C CN 1089232 C CN1089232 C CN 1089232C CN 96196203 A CN96196203 A CN 96196203A CN 96196203 A CN96196203 A CN 96196203A CN 1089232 C CN1089232 C CN 1089232C
Authority
CN
China
Prior art keywords
salt
amorphous state
acid
slightly water
soluble medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96196203A
Other languages
English (en)
Chinese (zh)
Other versions
CN1192677A (zh
Inventor
宫本操
织田寿久
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of CN1192677A publication Critical patent/CN1192677A/zh
Application granted granted Critical
Publication of CN1089232C publication Critical patent/CN1089232C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatment Of Sludge (AREA)
CN96196203A 1995-08-11 1996-08-08 将微水溶性药物转化为非晶态的方法 Expired - Fee Related CN1089232C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP20593695 1995-08-11
JP205936/95 1995-08-11
JP310401/95 1995-11-29
JP31040095 1995-11-29
JP31040195 1995-11-29
JP310400/95 1995-11-29

Publications (2)

Publication Number Publication Date
CN1192677A CN1192677A (zh) 1998-09-09
CN1089232C true CN1089232C (zh) 2002-08-21

Family

ID=27328563

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96196203A Expired - Fee Related CN1089232C (zh) 1995-08-11 1996-08-08 将微水溶性药物转化为非晶态的方法

Country Status (15)

Country Link
US (1) US6462093B1 (enrdf_load_stackoverflow)
EP (2) EP1356807A3 (enrdf_load_stackoverflow)
JP (1) JPWO9706781A1 (enrdf_load_stackoverflow)
KR (1) KR100498813B1 (enrdf_load_stackoverflow)
CN (1) CN1089232C (enrdf_load_stackoverflow)
AT (1) ATE255405T1 (enrdf_load_stackoverflow)
AU (1) AU702088B2 (enrdf_load_stackoverflow)
CA (1) CA2228907A1 (enrdf_load_stackoverflow)
CZ (1) CZ296072B6 (enrdf_load_stackoverflow)
DE (1) DE69630964T2 (enrdf_load_stackoverflow)
MX (1) MX9800717A (enrdf_load_stackoverflow)
NO (1) NO320486B1 (enrdf_load_stackoverflow)
NZ (1) NZ315089A (enrdf_load_stackoverflow)
TW (1) TW487582B (enrdf_load_stackoverflow)
WO (1) WO1997006781A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106793821A (zh) * 2014-08-29 2017-05-31 花王株式会社 含有难溶性多酚类的固体分散体的制造方法

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1741424B1 (en) * 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
JPH11130698A (ja) * 1997-10-31 1999-05-18 Freunt Ind Co Ltd アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
IE980115A1 (en) * 1998-02-16 2000-02-09 Biovail Internat Ltd Solubilizing delivery systems and method of manufacture
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
IL145140A0 (en) 1999-03-24 2002-06-30 Fmc Corp Improved aqueous solubility pharmaceutical formulations
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
ATE329579T1 (de) 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1738749A1 (en) 1999-12-23 2007-01-03 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
CA2418490A1 (en) * 2000-08-11 2002-02-21 Eisai Co., Ltd. Drug-containing solid dispersion having improved solubility
KR20020014570A (ko) * 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
US20040013736A1 (en) * 2000-09-25 2004-01-22 Tomio Nakano Process for producing medicinal solid dispersion
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
EP1340496A4 (en) * 2000-11-07 2004-04-14 Hisamitsu Pharmaceutical Co PHARMACEUTICAL PREPARATION OF THE PERCUTANEOUS ABSORPTION TYPE
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
WO2002083101A1 (de) * 2001-04-11 2002-10-24 Bayer Aktiengesellschaft Nimodipin-tablette mit kontrollierter freisetzung und verfahren zu deren herstellung
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
EP2272501B1 (en) 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
MY128945A (en) * 2002-04-16 2007-03-30 Kowa Co Solid dispersion composition
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ITMI20022748A1 (it) 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
DK1683524T3 (da) * 2003-11-14 2011-03-14 Ajinomoto Kk Dispergering på fast form eller medicinsk præparat på fast form af phenyalaninderivat
US8535716B2 (en) * 2004-04-01 2013-09-17 Tsrl, Inc. Methods and composition of extended delivery of water insoluble drugs
BRPI0509381A (pt) * 2004-04-08 2007-09-18 Wyeth Corp dispersão sólida, métodos de preparar a dispersão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência ou o excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal de tecidos endometrais, de tratar cáncer de mamas de um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, composição, forma de dosagem, e, uso de uma dispersão sólida
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
CA2569310A1 (en) * 2004-06-08 2005-12-29 Maura Murphy Pharmaceutical compositions
JP2006028130A (ja) * 2004-07-21 2006-02-02 Toa Eiyo Ltd ピモベンダン経口投与製剤
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
JP4509118B2 (ja) * 2004-10-06 2010-07-21 エルメッド エーザイ株式会社 医薬組成物及びその製造方法、並びに医薬組成物におけるジヒドロピリジン系化合物の安定化方法
US20090028948A1 (en) * 2004-12-31 2009-01-29 Iceutica Pty Ltd Nanoparticle composition and methods of synthesis thereof
CA2595894C (en) 2005-01-31 2013-09-10 Kanji Takada Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment
MX2007012642A (es) * 2005-04-11 2008-01-11 Abbott Lab Composiciones farmaceuticas que tienen perfiles mejorados de disolucion para farmacos poco solubles.
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20100016378A1 (en) * 2005-04-28 2010-01-21 Toshio Suzuki Method of preventing dihydropyridine compound from degradation
MX2007015171A (es) * 2005-06-02 2008-04-22 Thallion Pharmaceuticals Inc Formulacion que comprende farnesil dibenzodiazepinona y un tensoactivo farmaceuticamente aceptable.
EP1912730A2 (en) * 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
JP4974018B2 (ja) * 2005-08-24 2012-07-11 オリンパステルモバイオマテリアル株式会社 生体材料とその製造方法
EA015715B1 (ru) * 2005-08-29 2011-10-31 САНОФИ-АВЕНТИС Ю. Эс. ЭлЭлСи Твердая дисперсия, фармацевтическая композиция, включающая такую дисперсию, способ ее получения и применение для предотвращения и лечения заболеваний, связанных с бензодиазепиновыми рецепторами периферического типа
WO2007108463A1 (ja) 2006-03-23 2007-09-27 Shionogi & Co., Ltd. 溶解性が改善された固形製剤
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
WO2008120724A1 (ja) * 2007-03-30 2008-10-09 Ajinomoto Co., Inc. 固体分散体製剤
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
KR101443826B1 (ko) 2007-06-14 2014-09-23 가부시키가이샤 폴라 파마 의약조성물
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
WO2009038112A1 (ja) 2007-09-21 2009-03-26 Shionogi & Co., Ltd. Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009140105A2 (en) 2008-05-14 2009-11-19 Merck & Co., Inc. Formulations for cathepsin k inhibitors
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
SG174488A1 (en) * 2009-03-19 2011-10-28 Shionogi & Co Solid preparation containing npy y5 receptor antagonist
BRPI1014275B8 (pt) 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
CN101618012B (zh) * 2009-07-10 2012-07-04 东华大学 一种难溶性药物固体分散体制备方法
FR2954771B1 (fr) * 2010-04-23 2013-09-13 Mohamed Skiba Nouveau procede de synthese de copolymeres, terpolymeres et tetrapolymeres de cyclodextrines et leurs utilisations
CA2813510A1 (en) * 2010-10-14 2012-04-19 Abbott Gmbh & Co. Kg Curcuminoid solid dispersion formulation
WO2013058751A1 (en) * 2011-10-19 2013-04-25 Virginia Tech Intellectual Properties, Inc. Cellulose derivatives for enhancing bioavailability of flavonoids
JP5909796B2 (ja) * 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
BR112014030160A2 (pt) * 2012-07-23 2017-06-27 Dow Global Technologies Llc composição formadora de película, uso de uma composição formadora de película, película e cápsula dura
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN103191077B (zh) * 2013-04-18 2014-08-20 广东彼迪药业有限公司 一种格列齐特片及其制备方法
EP2832723B1 (en) * 2013-07-29 2017-02-15 Zentiva, a.s. Stabilised amorphous forms of Saxagliptin
JP2015189677A (ja) * 2014-03-27 2015-11-02 テバ製薬株式会社 ソリフェナシン非晶質体を含有する医薬組成物
WO2015174475A1 (ja) 2014-05-15 2015-11-19 株式会社セラバリューズ 経口摂取用組成物
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN107427462B (zh) * 2015-03-12 2023-08-29 杜邦营养美国有限公司 固态分散体
CN107920528A (zh) * 2015-09-04 2018-04-17 住友化学株式会社 组合物、组合物的制造方法和农药组合物
KR101912224B1 (ko) * 2017-02-20 2018-10-26 충남대학교산학협력단 타다라필 함유 고체 분산체, 이를 포함하는 약제학적 조성물 및 이의 제조방법
WO2019172420A1 (ja) * 2018-03-09 2019-09-12 協和発酵キリン株式会社 医薬組成物
CN111184692B (zh) * 2020-02-14 2021-10-26 南京大渊医美生物技术有限公司 一种白藜芦醇的制剂及其制备方法
CN111803447B (zh) * 2020-06-22 2022-08-09 三明学院 一种制备无定形药物的方法
WO2022090295A1 (en) * 2020-10-28 2022-05-05 Merck Patent Gmbh Method for producing an amorphous solid dispersion and pharmaceutical composition for stabilizing active pharmaceutical ingredients
CN113350309B (zh) * 2021-08-09 2021-11-12 北京五和博澳药业股份有限公司 一种难溶性药物渗透泵控释片剂及其制备方法
CN117257964B (zh) * 2023-10-25 2024-04-02 苏州大学 基于碳酸氢铵的微波诱导吲哚美辛原位无定形化增溶技术

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003023A1 (en) * 1986-10-31 1988-05-05 Mitsubishi Chemical Industries Limited Drug composition for treating liver diseases and process for its preparation
JPH02229A (ja) * 1987-12-16 1990-01-05 General Electric Co <Ge> オリゴマー組成物
JPH05306225A (ja) * 1992-04-27 1993-11-19 Taiyo Yakuhin Kogyo Kk 持続性製剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373049A (en) * 1943-02-05 1945-04-03 Du Pont Stabilization of organic substances
JPS5132718A (en) * 1974-09-13 1976-03-19 Yoshinobu Nakai Nanyoseiyakuhin no yoshutsusokudochosetsuho
US4083814A (en) * 1976-12-16 1978-04-11 General Electric Company Polycarbonate compositions plasticized with urea compounds
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS5649314A (en) * 1979-07-05 1981-05-02 Yamanouchi Pharmaceut Co Ltd Lasting pharmaceutical composition having prolonged action and its preparation
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
SE8604117D0 (sv) * 1986-09-29 1986-09-29 Kabivitrum Ab Composition
JPS63115815A (ja) * 1986-10-31 1988-05-20 Mitsubishi Kasei Corp 肝疾患治療薬組成物
US5510115A (en) * 1987-11-16 1996-04-23 Baxter Travenol Laboratories, Inc. Method and composition for administration of beneficial agent by controlled dissolution
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
JPH01305616A (ja) * 1988-06-02 1989-12-08 Toshiba Corp 半導体集積回路の出力回路
JP2750130B2 (ja) * 1988-08-31 1998-05-13 日清製粉株式会社 経口投与用組成物
DK0580860T4 (da) 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Fremgangsmåde til fremstilling af en fast dispersion
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE69326163T2 (de) 1992-12-23 2000-05-04 Saitec S.R.L., Castel Guelfo Di Bologna Verfahren zur herstellung von arzneiformen und kontrollierte freigabe und die soerhaltenen arzneiformen
DK19393D0 (da) * 1993-02-19 1993-02-19 Danochemo As Fremgangsmaade til fremstilling af et i vand dispergerbart pulverformigt carotenoidpraeparat
NO933375L (no) * 1993-02-24 1994-08-25 Marcus Kjemiske As Thor Vaskemiddelblanding
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
PL313733A1 (en) * 1993-09-23 1996-07-22 Du Pont Water-dispersible granular compositions for use in agriculture, obtained by thermal extrusion and method of obtaining them
WO1995026753A1 (fr) * 1994-04-01 1995-10-12 Tsumura & Co. Procede de production de comprimes a liberation prolongee et de comprimes enteriques
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003023A1 (en) * 1986-10-31 1988-05-05 Mitsubishi Chemical Industries Limited Drug composition for treating liver diseases and process for its preparation
JPH02229A (ja) * 1987-12-16 1990-01-05 General Electric Co <Ge> オリゴマー組成物
JPH05306225A (ja) * 1992-04-27 1993-11-19 Taiyo Yakuhin Kogyo Kk 持続性製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《沈阳药学院学报》9(4) 1992.4.30 刘淑英等硝苯喧-水溶性材料-肠溶性材料固体分散物的研究 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106793821A (zh) * 2014-08-29 2017-05-31 花王株式会社 含有难溶性多酚类的固体分散体的制造方法
US10894058B2 (en) 2014-08-29 2021-01-19 Kao Corporation Method for producing solid dispersion containing hardly soluble polyphenol
CN106793821B (zh) * 2014-08-29 2021-05-07 花王株式会社 含有难溶性多酚类的固体分散体的制造方法

Also Published As

Publication number Publication date
CN1192677A (zh) 1998-09-09
ATE255405T1 (de) 2003-12-15
EP1356807A3 (en) 2004-01-28
WO1997006781A1 (fr) 1997-02-27
CZ296072B6 (cs) 2006-01-11
CA2228907A1 (en) 1997-02-27
EP0852140A4 (enrdf_load_stackoverflow) 1998-07-29
EP0852140B1 (en) 2003-12-03
US6462093B1 (en) 2002-10-08
KR19990035836A (ko) 1999-05-25
AU702088B2 (en) 1999-02-11
NO320486B1 (no) 2005-12-12
CZ32698A3 (cs) 1998-06-17
JPWO9706781A1 (enrdf_load_stackoverflow) 1997-02-27
DE69630964D1 (de) 2004-01-15
NO980549L (no) 1998-04-02
NO980549D0 (no) 1998-02-09
DE69630964T2 (de) 2004-10-28
MX9800717A (es) 1998-11-30
AU6669396A (en) 1997-03-12
EP1356807A2 (en) 2003-10-29
EP0852140A1 (en) 1998-07-08
NZ315089A (en) 1999-06-29
TW487582B (en) 2002-05-21
KR100498813B1 (ko) 2006-02-28

Similar Documents

Publication Publication Date Title
CN1089232C (zh) 将微水溶性药物转化为非晶态的方法
KR102228157B1 (ko) 가열 용융 압출용 조성물 및 이것을 사용한 가열 용융 압출 성형물의 제조 방법
KR102315569B1 (ko) 히프로멜로오스 아세트산에스테르 숙신산에스테르를 사용한 스프레이 드라이용 용액 및 고체 분산체의 제조 방법
KR20040091099A (ko) 속방성 약학적 과립 조성물 및 그것의 연속적 제조 방법
CN1309375C (zh) 制备直接制片制剂与辅料的方法
Appelgren et al. A Novel Method for The Granulation and Coating of Pharmacologically Active Substances.
Pandya et al. Solid Dispersion Adsorbate–A Novel Technique for Dissolution Enhancemnet of Febuxostat
WO2002013792A1 (fr) Dispersion solide médicamenteuse à solubilité accrue
CN109730970A (zh) 德拉马尼速释制剂及其制备方法
WO2010081815A1 (en) Aqueous coacervate composition comprising poorly water-soluble biologically-active agents
JP2003116966A (ja) 直接錠剤化用調合物および補助剤の調合方法
Sonawane et al. Preparation and characterization of microwave-assisted candesartan cilexetil solid dispersions
CN104042561A (zh) 一种卡马西平共晶固体分散体及其制备方法
JPH09309834A (ja) 塩酸エホニジピン製剤の製造法
PATRA et al. Solubility enhancement of rivaroxaban by solid dispersion with polyethylene glycol 4000
WO2003105905A1 (en) Controlled release composition comprising felodipine and method of preparation thereof
JP2024091760A (ja) 非晶質固体分散体を含む複合物
CN102133203B (zh) 拉西地平分散片及其制备方法
JPH02167229A (ja) かわらたけ由来の蛋白多糖体の粒状製剤
Joshi et al. Solid Dispersion: A Technology for the Improvement of Oral Bioavailability of Poorly Soluble Drugs
CN113368069A (zh) 一种含有依折麦布的固体制剂及其制备方法
CN104188951A (zh) 一种二乙酰大黄酸组合物及其制备方法
Patil et al. Application of 22 level factorial design in formulation and evaluation of spherical agglomerates by solvent change method
Vyas et al. Preparation and characterization of solid dispersion of modafinil using PEG 6000 as hydrophilic carrier for improvement of dissolution profile
JP2003012517A (ja) 安定で溶出性の改善された非晶質組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20020821

Termination date: 20130808